Ferozsons Laboratories Ltd

Ferozsons Laboratories maintains a conservative capital structure with a debt-to-equity ratio of 0.35, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.94, suggesting it can cover short-term obligations but with limited excess capacity. Free cash flow of PKR 1.06 billion supports operational flexibility, though net cash is negative after subtracting total debt. Profitability metrics show a return on equity of 6.27% and a return on assets of 3.16%, both below the industry median for pharmaceutical firms. These figures suggest that Ferozsons is generating returns, but at a slower pace than its peers. Gross profit of PKR 7.99 billion represents 42.4% of revenue, which is in line with the industry average, but operating income of PKR 2.09 billion reflects a 11.1% margin, which is modest compared to leading firms in the sector. The company operates through three segments: Ferozsons, BF Biosciences, and others. The Ferozsons segment is the largest contributor, handling import, manufacture, and sale of pharmaceuticals and medical devices. BF Biosciences is engaged in similar activities, while the "others" segment includes sales of pharmaceutical and related products. Revenue concentration is not disclosed, but the lack of geographic diversification beyond Pakistan introduces a risk of overexposure to local economic and regulatory conditions. Growth trajectory is modest, with no specific numeric deltas provided for the current or next fiscal year. Historical revenue of PKR 18.86 billion indicates a stable but non-explosive growth pattern. The company's capital expenditure of PKR -668.69 million suggests a reduction in investment, which may signal a focus on cost control rather than expansion. Risk factors include medium liquidity risk and low dilution potential. The company's key flag is negative net cash after subtracting total debt, which could constrain its ability to fund new initiatives without external financing. No significant dilution sources are identified in the latest filings, and the probability of near-term dilution remains low. Recent events include the continued operation of subsidiaries BF Biosciences Limited and Farmacia, which are engaged in pharmaceutical import, manufacturing, and distribution. No major regulatory or legal filings have been disclosed in the latest period, and the company's focus remains on core pharmaceutical segments.